Fibromyalgia: History and Discovery

Fibromyalgia is a chronic condition of widespread musculoskeletal pain accompanied by fatigue, unrefreshing sleep, cognitive difficulty ("fibro fog"), and heightened tenderness to pressure. Its history is, above all, a history of naming — and of patients, the great majority of them women, being disbelieved for the better part of a century. Nineteenth-century physicians cataloged tender spots and "muscular rheumatism"; in 1904 Sir William Gowers christened the disorder fibrositis, a word implying inflammation that simply was never found. The modern era began in the 1970s, when Hugh Smythe and Harvey Moldofsky studied tender points and disturbed sleep; the term fibromyalgia took hold around 1976, clinical criteria were validated by Muhammad Yunus in 1981, and the American College of Rheumatology issued formal criteria in 1990 (revised 2010 and 2016). Today the leading scientific model is central sensitization — an amplification of pain signaling within the central nervous system — which at last frames fibromyalgia as a real neurobiological disorder rather than something "all in the head."

Table of Contents

  1. What Fibromyalgia Is
  2. Early Descriptions: Muscular Rheumatism and Tender Points
  3. 1904: Gowers Coins "Fibrositis" — a Lasting Misnomer
  4. The 1970s: Smythe, Moldofsky, Tender Points, and Sleep
  5. 1976–1981: From Fibrositis to Fibromyalgia
  6. 1990, 2010, 2016: The ACR Criteria
  7. Central Sensitization: The Modern Model
  8. "All in Your Head": A Long, Harmful Dismissal
  9. Legacy and Where the Science Stands
  10. Research Papers and References
  11. Connections

What Fibromyalgia Is

Fibromyalgia is a chronic disorder defined by widespread pain — pain felt on both sides of the body, above and below the waist — together with profound fatigue, sleep that does not restore, and a striking increase in tenderness, so that ordinary pressure or touch can register as pain. Most people with it also describe cognitive fog, headaches, irritable bowel symptoms, heightened sensitivity to light, sound, and temperature, and a constellation of other complaints. It is common, affecting an estimated 2 to 4 percent of the population, and it is diagnosed far more often in women than in men.

For most of its recorded history, the great obstacle to understanding fibromyalgia was the absence of anything to see. Blood tests come back normal. X-rays and scans show no damage. Muscle biopsies reveal no disease. Because the tools of nineteenth- and twentieth-century medicine found no lesion, the condition was repeatedly explained away — first as inflammation that was never there, later as a purely psychological complaint. The history that follows is largely the story of medicine slowly learning to take an "invisible" pain seriously, and finding, at last, that the problem lies not in the muscles but in how the nervous system itself processes pain.

Back to Table of Contents

Early Descriptions: Muscular Rheumatism and Tender Points

Pain of the kind we now call fibromyalgia is far older than the modern label. For centuries, diffuse aching of the muscles was simply grouped under rheumatism, and later muscular rheumatism — a broad catch-all for pain that did not fit a joint disease. The first reasonably specific clinical descriptions emerged in the early nineteenth century. A Scottish surgeon at the University of Edinburgh, William Balfour, is widely credited with characterizing the condition around 1816, describing painful nodules in muscle that were tender on pressure and from which pain seemed to radiate outward; he is often cited as among the first to note what would later be called tender points. These early attributions come from historical reviews rather than from sources we can independently verify in primary form, and they are offered here as the standard account rather than as established fact.

Through the mid-nineteenth century, other physicians added pieces. The German physician Robert Froriep is commonly cited (around 1843) for describing tender, hardened areas in muscle — rendered in German as Muskelschwiele, or "muscle calluses" — in patients with rheumatic complaints. In France, work on points douloureux (painful points) and referred neuralgic pain explored similar terrain. Later in the century, the American neurologist George Miller Beard described patients with widespread pain, exhaustion, and emotional distress under the now-abandoned diagnosis of neurasthenia — a label that, in hindsight, swept up many people who would today be recognized as having fibromyalgia or chronic fatigue.

What unites these early accounts is a recurring pattern of observation: real, reproducible tenderness at characteristic spots, diffuse muscular aching, fatigue, and disturbed well-being, in patients whose tissues looked structurally normal. The phenomena were being seen clearly; what was missing was a coherent explanation. That gap — vivid symptoms with no visible cause — would shape, and distort, the next century of thinking.

Back to Table of Contents

1904: Gowers Coins "Fibrositis" — a Lasting Misnomer

In 1904, the eminent British neurologist Sir William Richard Gowers proposed a name that would dominate the field for some seventy years. Writing in the British Medical Journal in a paper on lumbago (commonly titled "Lumbago: Its Lessons and Analogues"), Gowers suggested that the muscular pain of these conditions be called fibrositis — literally, inflammation (-itis) of the fibrous tissue. The term was elegant, memorable, and immediately popular. It gave clinicians a single word for a frustrating, hard-to-classify pain, and for decades "fibrositis" appeared throughout the medical literature and in everyday practice.

There was, however, a fundamental problem buried in the name. The -itis suffix asserted that the disorder was inflammatory, and over the following decades investigators looked, repeatedly, for that inflammation in the muscles and fibrous tissues of affected patients — and did not find it. Microscopic study of the painful tissue revealed no consistent inflammatory changes, no characteristic lesion, nothing to justify the "-itis." The word, in other words, described a mechanism that did not exist. Fibrositis was a misnomer, and an influential one: it pointed generations of doctors and researchers toward a dead end, encouraging a search for tissue inflammation that was never going to be found.

The legacy of this naming error was double-edged. On one hand, "fibrositis" at least gave the condition a recognized identity and kept it on the medical map. On the other, when the promised inflammation failed to materialize, the credibility of the whole diagnosis suffered — and the vacuum left by the discredited inflammatory theory was, for much of the twentieth century, filled by the assumption that the pain must therefore be psychological. Correcting Gowers’ misnomer would take until the 1970s, and undoing its downstream damage to how patients were treated has taken far longer.

Back to Table of Contents

The 1970s: Smythe, Moldofsky, Tender Points, and Sleep

The decisive shift toward the modern understanding came in the 1970s through the work of two Canadian researchers in Toronto: the rheumatologist Hugh A. Smythe — often called the "grandfather" of modern fibromyalgia — and the sleep researcher and psychiatrist Harvey Moldofsky. Smythe reconceived the disorder not as a vague rheumatism but as a definable, generalized pain syndrome with consistent features: widespread pain, fatigue, morning stiffness, poor sleep, and reproducible tenderness at specific anatomical sites. His articulation of characteristic tender points — precise locations that are painful under modest pressure — gave the condition, for the first time, a usable clinical fingerprint.

Moldofsky’s contribution was to connect the pain to sleep. In landmark sleep-laboratory experiments, he documented that patients with the syndrome had a disturbance of deep (slow-wave) sleep, marked by intrusions of fast "alpha" brain-wave activity into the deep sleep that normally restores the body — the phenomenon often described as the alpha–delta sleep anomaly and as non-restorative sleep. Strikingly, when healthy volunteers had their deep sleep deliberately interrupted, they began to develop the same diffuse muscle pain and tenderness, suggesting that disordered sleep was not merely a consequence of the pain but could help generate it. This linkage of unrefreshing sleep to widespread pain became, and remains, one of the central pillars of fibromyalgia science.

Together, Smythe and Moldofsky transformed a discredited label into a researchable clinical entity. Their joint work in the mid-1970s — including the influential contributions on what was still being called the "fibrositis syndrome" — supplied both the symptom profile (widespread pain, tender points, fatigue, non-restorative sleep) and the first plausible physiological thread tying those symptoms together. It set the stage for renaming the disorder and for the formal diagnostic criteria that followed.

Back to Table of Contents

1976–1981: From Fibrositis to Fibromyalgia

With inflammation ruled out, the inflammatory name had to go. The replacement term, fibromyalgia, is built from honest, descriptive roots — Latin fibra (fibrous tissue), Greek myo (muscle), and algia (pain): literally, "pain in the muscles and fibrous tissue," making no false claim about a cause. The word is generally credited to the American physician Philip Kahler Hench, who is reported to have used "fibromyalgia" around 1976. (He should not be confused with his father, the Nobel laureate Philip Showalter Hench of cortisone fame.) Over the latter half of the 1970s the new term gradually displaced "fibrositis" in the literature.

The pivotal step in making fibromyalgia a rigorously defined diagnosis came in 1981, when Muhammad B. Yunus and colleagues at the University of Illinois published the first controlled clinical study of the syndrome. By systematically comparing patients with healthy controls, Yunus’ team validated the characteristic symptom cluster — widespread pain, multiple tender points, fatigue, poor sleep, and associated features — and proposed the first data-based diagnostic criteria. This was a watershed: it moved fibromyalgia from clinical impression to evidence, demonstrating that the symptoms and tender points reliably distinguished patients from people without the condition.

Yunus also advanced a unifying idea that still organizes the field. He observed that fibromyalgia overlapped with a family of other puzzling conditions — irritable bowel syndrome, tension and migraine headache, certain pelvic and bladder pain syndromes — and proposed that they shared a common underlying mechanism, later framed as central sensitivity syndromes. By the early 1980s, then, fibromyalgia had a defensible name, validated criteria, and a conceptual home; the remaining task was to standardize its diagnosis across the wider medical community.

Back to Table of Contents

1990, 2010, 2016: The ACR Criteria

The landmark act of legitimization came in 1990, when the American College of Rheumatology (ACR) published, through its Multicenter Criteria Committee, the first widely adopted classification criteria for fibromyalgia. The 1990 criteria required two things: (1) a history of widespread pain present for at least three months, and (2) pain on palpation in at least 11 of 18 specified tender point sites. Tested against patients with other rheumatic conditions, this combination performed well (a sensitivity of about 88 percent and specificity of about 81 percent). For the first time, researchers everywhere could identify fibromyalgia patients by a shared standard, and the diagnosis entered the medical mainstream.

The tender-point requirement, however, had practical drawbacks. Examining 18 points by thumb pressure was operator-dependent and inconsistently performed; many physicians never learned the technique; and the count captured only part of what patients actually experienced — it said little about fatigue, sleep, cognition, or the many other symptoms. So in 2010, a group led by Frederick Wolfe published preliminary diagnostic criteria that abandoned the tender-point examination altogether. The 2010 criteria instead combined a Widespread Pain Index (WPI) — counting the number of body regions in which the patient has pain — with a Symptom Severity (SS) scale rating fatigue, unrefreshing sleep, cognitive symptoms, and other complaints. This recast fibromyalgia as a symptom-based diagnosis reflecting the patient’s whole experience rather than a tally of sore spots.

A further 2016 revision refined the 2010/2011 framework: it required generalized pain in at least four of five defined body regions (to avoid mislabeling localized or regional pain as fibromyalgia), merged the physician-administered and self-report versions into one consistent instrument, and clarified that fibromyalgia could be diagnosed alongside other illnesses rather than being a diagnosis of exclusion. Taken together, the arc from 1990 to 2016 traces a deliberate movement away from counting tender points and toward listening to the breadth of a patient’s symptoms — a quietly important shift in how seriously the patient’s own report is weighed.

Back to Table of Contents

Central Sensitization: The Modern Model

The most important conceptual advance of the past few decades has been a change in where the problem is thought to lie. For a century, the search focused on the muscles and connective tissue — the periphery — and found nothing. The leading contemporary model relocates the disorder to the central nervous system itself and is called central sensitization: an amplified, "turned-up" response of the brain and spinal cord to sensory input. In this framework, fibromyalgia is understood not as damaged muscles but as a disturbance in how pain is processed — the volume control on pain has been set too high, so that normal signals are experienced as painful (allodynia) and painful signals are experienced as intensely so (hyperalgesia).

This model is supported by converging lines of evidence. Functional brain imaging studies have shown that, given the same controlled pressure, people with fibromyalgia activate pain-processing regions of the brain more strongly than people without it — objective signatures of augmented central pain processing in the somatosensory cortex and related areas. Researchers have also documented altered levels of pain-signaling neurotransmitters in the central nervous system, abnormal descending pain-inhibition (the body’s built-in pain "brakes" working poorly), and the heightened sensitivity to sound, light, heat, and pressure that the central-sensitization idea predicts. The framework also explains why fibromyalgia so often travels with irritable bowel syndrome, chronic headache, and other "central sensitivity syndromes" that share the same amplifying mechanism — the unifying insight Yunus had proposed years earlier.

It is worth being precise about the status of this idea: central sensitization is the leading and best-supported model, and it has reframed fibromyalgia as a genuine, measurable neurobiological condition. It is not, however, a complete or final explanation. Why central sensitization develops — the roles of genetics, physical or emotional trauma, infection, autonomic dysfunction, small-fiber nerve changes, and disturbed sleep — remains under active investigation, and the science continues to evolve. What has decisively changed is the recognition that the pain is real and rooted in the nervous system, not imagined.

Back to Table of Contents

"All in Your Head": A Long, Harmful Dismissal

No honest history of fibromyalgia can omit the way patients were treated along the way. Once Gowers’ promised inflammation failed to appear and no lesion could be found, a damaging logic took hold in much of twentieth-century medicine: if nothing could be seen, perhaps there was nothing physically wrong. The condition was frequently dismissed as psychogenic rheumatism, as a manifestation of depression or anxiety, as malingering, or simply as pain that was — in the phrase countless patients have heard — "all in your head." Because the diagnosis fell most heavily on women, it became entangled with long-standing and harmful stereotypes about women’s pain being exaggerated, emotional, or imagined.

The human cost of this was, and is, substantial. Patients describe years-long delays before diagnosis, repeated normal test results offered as proof that nothing was wrong, the erosion of being disbelieved by clinicians and sometimes by family, and the isolation and self-doubt that follow. Modern research on fibromyalgia stigma documents exactly this pattern — disbelief driven by the invisibility of the symptoms, the absence of a confirming test, long diagnostic odysseys, and gendered assumptions — and finds that the sense of not being believed often persists even after a formal diagnosis is made. This is not a historical footnote; it shapes care today.

The shift to a central-sensitization understanding matters here for reasons beyond the laboratory. By locating fibromyalgia in measurable changes in the nervous system, the modern model directly counters the "it’s all in your head" dismissal: the pain is real, it has a biological basis, and the patient’s report of it is trustworthy. Recognizing this history is part of treating people with fibromyalgia respectfully — acknowledging that many endured not only chronic pain but the additional injury of being disbelieved by the very system meant to help them.

Back to Table of Contents

Legacy and Where the Science Stands

The trajectory of fibromyalgia’s history is a study in how medicine corrects itself, slowly. A nineteenth-century pattern of tender points and muscular aching was named, in 1904, for an inflammation that did not exist; that misnomer was finally replaced in the 1970s by an honest, descriptive term, anchored by Smythe and Moldofsky’s tender-point and sleep research and validated by Yunus’ controlled study in 1981. Formal criteria in 1990 made the diagnosis reproducible, and their revision in 2010 and 2016 moved the definition from counting sore spots toward listening to the patient’s whole symptom picture. Underlying it all, the rise of the central-sensitization model has reframed fibromyalgia as a real disorder of nervous-system pain processing.

Much remains unsettled, and the page does not pretend otherwise. There is still no single confirmatory laboratory test; diagnosis rests on clinical assessment of symptoms. The root causes of central sensitization — and the relative contributions of genetics, trauma, infection, sleep disruption, autonomic and small-fiber nerve changes — are still being worked out, and overlap with related conditions such as ME/CFS and chronic widespread pain continues to be actively studied. Treatment remains multimodal (exercise and movement, sleep care, certain medications, and psychological and self-management approaches) rather than curative.

What this history offers a reader today is perspective and reassurance in equal measure. Fibromyalgia is not new, not imaginary, and not a sign of weakness; it is a long-recognized, increasingly well-understood disorder whose sufferers were too often failed by the medicine of their time. Understanding how the diagnosis evolved — from muscular rheumatism to fibrositis to fibromyalgia, and from "all in your head" to central sensitization — is part of taking the condition, and the people who live with it, seriously.

Back to Table of Contents

Research Papers and References

The references below combine landmark peer-reviewed papers in the history and diagnosis of fibromyalgia with curated PubMed topic-search links into the broader literature. Where a specific paper’s identifier could be confirmed, a direct DOI or PubMed (PMID) link is given; otherwise a PubMed topic search is provided. Historical primary sources — such as Gowers’ 1904 British Medical Journal paper on lumbago — are named in the article as historical documents rather than as modern citations. Each link opens at its source in a new tab.

  1. Inanici F, Yunus MB. History of fibromyalgia: past to present. Current Pain and Headache Reports. 2004;8(5):369-378. — doi:10.1007/s11916-996-0010-6 (PMID 15361321)
  2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis & Rheumatism. 1990;33(2):160-172. — PMID 2306288
  3. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research. 2010;62(5):600-610. — doi:10.1002/acr.20140
  4. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism. 2016;46(3):319-329. — doi:10.1016/j.semarthrit.2016.08.012
  5. Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bulletin on the Rheumatic Diseases. 1977-1978;28(1):928-931. — PMID 199304
  6. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism. 1981;11(1):151-171. — doi:10.1016/0049-0172(81)90096-2
  7. Reynolds MD. The development of the concept of fibrositis. Journal of the History of Medicine and Allied Sciences. 1983;38(1):5-35. — doi:10.1093/jhmas/38.1.5
  8. Smythe HA. Fibrositis syndrome: a historical perspective. Journal of Rheumatology Supplement. 1989;19:2-6. — PMID 2691679
  9. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions. Seminars in Arthritis and Rheumatism. 2007;36(6):339-356. — doi:10.1016/j.semarthrit.2006.12.009
  10. Fibromyalgia and central sensitization — mechanisms and pain processing — PubMed: fibromyalgia central sensitization pain processing
  11. History and evolution of fibromyalgia concepts and criteria — PubMed: history and evolution of fibromyalgia criteria
  12. Stigma and the experience of being disbelieved in fibromyalgia — PubMed: fibromyalgia stigma and patient experience
  13. Moldofsky and non-restorative (alpha–delta) sleep in fibromyalgia — PubMed: Moldofsky non-restorative sleep in fibromyalgia
  14. Functional neuroimaging of augmented pain processing in fibromyalgia — PubMed: neuroimaging of augmented pain in fibromyalgia

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents